Hematology Frontier

The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13 to 16, 2024, in Madrid, Spain. This conference, the largest international event in the field of hematology in Europe, attracts numerous renowned experts and scholars each year to share and discuss innovative ideas, the latest scientific research, and clinical findings in hematology. At this year's conference, the research team led by Professor Wenming Chen from Beijing Chao-Yang Hospital , Capital Medical University presented their findings in an oral presentation (S209) on the Phase II study of all-human BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma (RRMM). To gain deeper insights into the latest research in the RRMM field, Oncology Frontier - Hematology Frontier invited Professor Wenming Chen for an in-depth discussion.

The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held from June 13-16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world each year to share and discuss innovative concepts and the latest scientific and clinical research results in hematology. At this year's conference, Professor Xiaohui Zhang's team from Peking University People's Hospital performed outstandingly, with four studies selected for oral presentation, and one study awarded the YoungEHA Best Abstract Award, making it one of the four global award-winning studies of the year and the only one from China to receive this honor. This achievement not only highlights the team's exceptional strength but also showcases the potential and capabilities of Chinese researchers. "Oncology Frontier - Hematology Frontier" specially invited Professor Xiaohui Zhang and his team members for a roundtable discussion to share their research findings, covering non-invasive diagnostic techniques, mechanisms of CAR-T cell therapy toxicity in relapsed/refractory T-cell leukemia, prognosis models for mixed phenotype acute leukemia (MPAL), and innovative clinical research in immune thrombocytopenia (ITP).

The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held from June 13-16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world each year to share and discuss innovative concepts and the latest scientific and clinical research results in hematology. At this year's conference, Professor Jun Ma's team from the Harbin Institute of Hematology and Oncology presented real-world study results on the treatment of acute myeloid leukemia (AML) with mitoxantrone liposome. "Oncology Frontier - Hematology Frontier" invited Professor Jun Ma for an interview to interpret the study content, discuss field development trends, and introduce the outstanding performance of Chinese teams at this conference.

The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, Spain, from June 13 to 16, 2024. The EHA conference featured numerous captivating presentations, particularly in the area of non-remission acute myeloid leukemia (NR-AML), which attracted significant attention. A study by Professor Zhijie Wei's team from Beijing Lu Daopei Hospital, targeting NR-AML patients undergoing salvage haploidentical hematopoietic stem cell transplantation (haplo-HCT) (Abstract No.: P1324), was included in the conference abstracts. This study aimed to retrospectively analyze clinical and follow-up data of NR-AML patients treated with haplo-HCT at the hospital, summarizing the impact of adding unrelated cord blood infusion on patient survival and the incidence of severe (grade III-IV) graft-versus-host disease (GVHD). To provide a deeper understanding of this study, Professor Zhijie Wei was invited to give a detailed introduction, which is summarized below.

The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, Spain, from June 13 to 16, 2024. As the largest international conference in the field of hematology in Europe, it annually attracts experts and scholars from around the world to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, several studies from Professor Jia Wei's team at Tongji Hospital, Huazhong University of Science and Technology, were selected for poster or electronic poster presentations. This report highlights two studies in the field of aggressive B-cell lymphoma (P2090 and P1164), aiming to provide references for improving the long-term survival and optimizing treatment options for relapsed/refractory B-cell lymphoma.

The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13 to 16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, a study by Professor Yang Liang's team from Sun Yat-sen University Cancer Center on "Bone Marrow Ecosystem Formation and Secondary Resistance to Anti-CD38 Therapy in Multiple Myeloma" was selected for an oral presentation (S198). This study provides significant insights and references for optimizing resistance management in anti-CD38 therapy for multiple myeloma. We invited Professor Yang Liang for an interview to delve into the study's content and its clinical implications, as well as to highlight future research directions in this field.

The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held from June 13 to 16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world every year to share and discuss innovative ideas and the latest scientific and clinical research results in hematology. At this year's conference, a study by Professor Liang Wang's team from Beijing Tongren Hospital, Capital Medical University, was selected for poster presentation (P1187). The study, based on a PRISMA-compliant meta-analysis and systematic review, explored the best treatment options for vitreoretinal lymphoma (VRL). To provide a better understanding of the research findings, "Oncology Frontier - Hematology Frontier" invited the first author of the study, Dr.  Jing Gao, to introduce the research in detail and Professor Liang Wang to provide an in-depth commentary.

The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13 to 16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world each year to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, a study by Dr. Fang Xu from Prof. Yue Lu's team at Beijing Lu Daopei Hospital was selected for poster presentation (P1299). The study compared the application of ATG-T vs. ATLG in TBI-based conditioning for alternative donor allogeneic hematopoietic stem cell transplantation. We invited Dr. Fang Xu to introduce the study and provide insights for clinical practice or future research.

The 29th Annual Congress of the European Hematology Association (EHA) took place from June 13 to 16, 2024, in Madrid, Spain. Renowned as the "Olympics" of European hematology, the EHA Congress is celebrated for its cutting-edge scientific discussions and extensive clinical research findings, drawing global attention. Among the numerous highlights of this year's event was the EHA-CSH Joint Symposium, which brought together leading experts from China and Europe to discuss the latest advancements in T-cell acute lymphoblastic leukemia (T-ALL). Oncology Frontier – Hematology Frontier had the privilege of interviewing Professor Jianxiang Wang, co-chair of the symposium and Chief Clinical Expert at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to share his insights on the event, key highlights of the EHA-CSH symposium, and his own research presentations and future directions.

The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13 to 16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, Professor Zhihui Li from Beijing GoBroad Boren Hospital presented research on the "Safety and Efficacy of Luspatercept in Allogeneic Transplantation for Malignant Hematologic Diseases." This study provides valuable insights for clinical practice. Oncology Frontier - Hematology Frontier had the opportunity to interview Dr. Zhihui Li at the conference to delve into the study's findings and their clinical implications.